Dokumentacja Integracyjna SMPL
25.0.0 - STU1 Poland flag

: PsoriasisActiveSubstance - TTL Representation

Active as of 2024-09-17

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:ValueSet ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "PLSMPLPsoriasisActiveSubstance"] ; # 
  fhir:meta [
    ( fhir:profile [
fhir:v "https://ezdrowie.gov.pl/fhir/StructureDefinition/PLSMPLAdminValueSet"^^xsd:anyURI ;
fhir:link <https://ezdrowie.gov.pl/fhir/StructureDefinition/PLSMPLAdminValueSet>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet PLSMPLPsoriasisActiveSubstance</b></p><a name=\"PLSMPLPsoriasisActiveSubstance\"> </a><a name=\"hcPLSMPLPsoriasisActiveSubstance\"> </a><a name=\"PLSMPLPsoriasisActiveSubstance-pl-PL\"> </a><ul><li>Include these codes as defined in <a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html\"><code>https://ezdrowie.gov.pl/fhir/CodeSystem/PLActiveSubstanceCodeCodeSystem</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-adalimumab\">adalimumab</a></td><td>Adalimumab (dostępny w terapii pacjentów od 4 r.ż.)</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-etanercept\">etanercept</a></td><td>Etanercept (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-infliksymab\">infliksymab</a></td><td>Infliksymab</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-iksekizumab\">iksekizumab</a></td><td>Iksekizumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-sekukinumab\">sekukinumab</a></td><td>Sekukinumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-ustekinumab\">ustekinumab</a></td><td>Ustekinumab (dostępny w terapii pacjentów od 6 r.ż.)</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-ryzankizumab\">ryzankizumab</a></td><td>Ryzankizumab</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-guselkumab\">guselkumab</a></td><td>Guselkumab</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-certolizumab_pegol\">certolizumab_pegol</a></td><td>Certolizumab pegol</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-tyldrakizumab\">tyldrakizumab</a></td><td>Tyldrakizumab</td></tr><tr><td><a href=\"CodeSystem-PLActiveSubstanceCodeCodeSystem.html#PLActiveSubstanceCodeCodeSystem-bimekizumab\">bimekizumab</a></td><td>Bimekizumab</td></tr></table></li></ul></div>"
  ] ; # 
  fhir:url [ fhir:v "https://ezdrowie.gov.pl/fhir/ValueSet/PLSMPLPsoriasisActiveSubstance"^^xsd:anyURI] ; # 
  fhir:version [ fhir:v "25.0.0"] ; # 
  fhir:name [ fhir:v "PLSMPLPsoriasisActiveSubstance"] ; # 
  fhir:title [ fhir:v "PsoriasisActiveSubstance"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v "false"^^xsd:boolean] ; # 
  fhir:date [ fhir:v "2024-09-17T15:37:37+02:00"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "CeZ"] ; # 
  fhir:contact ( [
fhir:name [ fhir:v "CeZ" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "https://ezdrowie.gov.pl" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "Słownik dostępnych substancji czynnych w programie lekowym 'Łuszczyca'"] ; # 
  fhir:useContext ( [
fhir:code [
fhir:system [ fhir:v "urn:oid:0.0.0.0.0"^^xsd:anyURI ] ;
fhir:code [ fhir:v "setOfValueSet" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
      ( fhir:coding [
fhir:system [ fhir:v "https://ezdrowie.gov.pl/fhir/CodeSystem/PLSMPLSetOfValueSetsCodeSystem"^^xsd:anyURI ] ;
fhir:code [ fhir:v "slowniki_substancji" ]       ] )     ]
  ] ) ; # 
  fhir:jurisdiction ( [
    ( fhir:coding [
fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ;
fhir:code [ fhir:v "PL" ] ;
fhir:display [ fhir:v "Poland" ]     ] )
  ] ) ; # 
  fhir:compose [
    ( fhir:include [
fhir:system [ fhir:v "https://ezdrowie.gov.pl/fhir/CodeSystem/PLActiveSubstanceCodeCodeSystem"^^xsd:anyURI ] ;
      ( fhir:concept [
fhir:code [ fhir:v "adalimumab" ] ;
fhir:display [ fhir:v "Adalimumab (dostępny w terapii pacjentów od 4 r.ż.)" ]       ] [
fhir:code [ fhir:v "etanercept" ] ;
fhir:display [ fhir:v "Etanercept (dostępny w terapii pacjentów od 6 r.ż.)" ]       ] [
fhir:code [ fhir:v "infliksymab" ] ;
fhir:display [ fhir:v "Infliksymab" ]       ] [
fhir:code [ fhir:v "iksekizumab" ] ;
fhir:display [ fhir:v "Iksekizumab (dostępny w terapii pacjentów od 6 r.ż.)" ]       ] [
fhir:code [ fhir:v "sekukinumab" ] ;
fhir:display [ fhir:v "Sekukinumab (dostępny w terapii pacjentów od 6 r.ż.)" ]       ] [
fhir:code [ fhir:v "ustekinumab" ] ;
fhir:display [ fhir:v "Ustekinumab (dostępny w terapii pacjentów od 6 r.ż.)" ]       ] [
fhir:code [ fhir:v "ryzankizumab" ] ;
fhir:display [ fhir:v "Ryzankizumab" ]       ] [
fhir:code [ fhir:v "guselkumab" ] ;
fhir:display [ fhir:v "Guselkumab" ]       ] [
fhir:code [ fhir:v "certolizumab_pegol" ] ;
fhir:display [ fhir:v "Certolizumab pegol" ]       ] [
fhir:code [ fhir:v "tyldrakizumab" ] ;
fhir:display [ fhir:v "Tyldrakizumab" ]       ] [
fhir:code [ fhir:v "bimekizumab" ] ;
fhir:display [ fhir:v "Bimekizumab" ]       ] )     ] )
  ] . #